Prescription medicine
Ivabradine Brand names: Corlanor
Ivabradine (Corlanor) is a prescription medicine with an FDA approval on record since 2015. FDA's NDC Directory lists it from 11 generic labelers, and pharmacies paid $0.761 per ivabradine HCl 5 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- A presentation discontinued
Check it at the source: the ivabradine FDA label on DailyMed (effective November 10, 2025); the NDA 206143 record on Drugs@FDA; every ivabradine label on DailyMed.
Highlights of the record
FDA label of November 10, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageINDICATIONS AND USAGE Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.
Forms and strengths
- 5 mg
- 7.5 mg
- 5 mg/5ml
Film-coated tablet; tablet; solution.
On the market
- Earliest approval on file
- April 15, 2015 Corlanor, Amgen Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 6 first December 30, 2021; 6 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 12 of which 11 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- June 12, 2027 Corlanor tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.761 per tablet Ivabradine HCl 5 mg tablet
- Shortage (FDA)
- None current 3 past records
- Recalls by its makers (FDA)
- 2 since 2026 0 Class I among all firms' recalls; latest June 4, 2026
- FAERS reports
- 6,817 through July 30, 2026
What is ivabradine used for?
From the label: indications and usageINDICATIONS AND USAGE Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older. […]
Conditions named in the indications of ivabradine's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker.
Source: FDA drug label (Corlanor), Amgen Inc, effective November 10, 2025 (SPL set 92018a65-38f6-45f7-91d4-a34921b81d0d), via openFDA; the full label on DailyMed
What does the patient leaflet for ivabradine say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about Corlanor?Corlanor may cause serious side effects in adults and children, including: Harm to an unborn baby. Females who are able to get pregnant: ○ Must use effective birth control during treatment with Corlanor. ○ Tell your doctor right away if you become pregnant during treatment with Corlanor. Increased risk of irregular or rapid heartbeat (atrial fibrillation or heart rhythm problems). Tell your doctor if you feel any of the following symptoms of an irregular or rapid heartbeat: ○ heart is pounding or racing (palpitations). ○ chest pressure. ○ worsened shortness of breath. ○ near fainting or fainting. Sl ow er than normal heart rate (bradycardia). Tell your doctor if you have: ○ a slowing of heart rate, or ○ symptoms of a slow heart rate such as dizziness, fatigue, lack of energy. In young children signs and symptoms of slow heart rate may include: poor feeding, difficulty breathing or turning blue.
From the patient leaflet: What should you avoid while taking Corlanor?Avoid drinking grapefruit juice and taking St. John’s wort during treatment with Corlanor. These can affect the way Corlanor works and may cause serious side effects.
From the patient leaflet: How should I store Corlanor?Store Corlanor at room temperature between 68°F to 77°F (20°C to 25°C). Keep Corlanor ampules in the unopened child-resistant foil pouch until ready to use, to protect from light. Do not save or reuse any leftover Corlanor oral solution. Corlanor oral solution is sterile and does not contain a preservative. Keep Corlanor and all medicines out of the reach of children.
Source: FDA drug label (Corlanor), Amgen Inc, effective November 10, 2025 (SPL set 92018a65-38f6-45f7-91d4-a34921b81d0d), via openFDA; the full label on DailyMed
Is there a generic for ivabradine (Corlanor)?
The FDA approved the first generic ivabradine on December 30, 2021. 6 generic applications are approved; 6 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists ivabradine from 11 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 4 patents for Corlanor tablets: the compound patent runs to December 12, 2026 (pediatric exclusivity to June 12, 2027). A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2015 earliest approval on file
- 2021 first generic approved
- 2027 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for ivabradine (Corlanor)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.761 per Ivabradine HCl 5 mg tablet, down 75% from $3.02 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Ivabradine HCl 5 mg tablet (generic)
- Corlanor 7.5 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ivabradine HCl 5 mg tablet | Generic | $0.761 per tablet | $22.82 | -75% |
| Ivabradine HCl 7.5 mg tablet | Generic | $0.640 per tablet | $19.20 | -75% |
| Corlanor 5 mg tablet | Brand | $10.01 per tablet | $300.31 | +0.2% |
| Corlanor 7.5 mg tablet | Brand | $10.00 per tablet | $299.93 | -0.2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is ivabradine in shortage?
No ivabradine presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 3 records are all marked to be discontinued, the latest updated March 24, 2026. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28) | Amgen Inc. | To Be Discontinued | March 24, 2026 |
| Corlanor, Tablet, eq. 5 mg base (NDC 55513-800-60) | Amgen Inc. | To Be Discontinued | March 24, 2026 |
| Corlanor, Tablet, eq. 7.5 mg base (NDC 55513-810-60) | Amgen Inc. | To Be Discontinued | March 24, 2026 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has ivabradine been recalled?
The FDA's Enforcement Report lists 2 recalls naming ivabradine since 2026: 0 Class I (the most serious), 2 Class II, 0 Class III; 2 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| June 4, 2026 | Class II | Amgen, Inc. | Presence of Foreign Substance. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the ivabradine label say about other medicines?
The ivabradine label names 9 other medicines in its interaction, contraindication or warning sections. The labels of 14 other medicines name ivabradine. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Amiodarone | drug interactions | The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). |
| Clarithromycin | drug interactions | The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g. … |
| Digoxin | drug interactions | The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). |
| Diltiazem | drug interactions | Avoid concomitant use of moderate CYP3A4 inhibitors when using Corlanor. Examples of moderate CYP3A4 inhibitors include diltiazem, verapamil, and grapefruit juice [ s ee Warnings and Precautions ( 5.3 ) and Clinical Pharmacology ( 12.3 )]. |
| Itraconazole | drug interactions | The concomitant use of strong CYP3A4 inhibitors is contraindicated [ s ee Contraindications ( 4 ) and Clinical Pharmacology ( 12.3 )]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g. … |
| Nefazodone | drug interactions | … macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. |
| Nelfinavir | drug interactions | … itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. |
| Phenytoin | drug interactions | Avoid concomitant use of CYP3A4 inducers when using Corlanor. Examples of CYP3A4 inducers include St. John’s wort, rifampicin, barbiturates, and phenytoin [ s ee Clinical Pharmacology ( 12.3 )]. |
| Verapamil | drug interactions | Avoid concomitant use of moderate CYP3A4 inhibitors when using Corlanor. Examples of moderate CYP3A4 inhibitors include diltiazem, verapamil, and grapefruit juice [ s ee Warnings and Precautions ( 5.3 ) and Clinical Pharmacology ( 12.3 )]. |
Other labels that name ivabradine
Source: FDA drug label (Corlanor), Amgen Inc, effective November 10, 2025 (SPL set 92018a65-38f6-45f7-91d4-a34921b81d0d), via openFDA; the full label on DailyMed
What do FAERS reports show for ivabradine?
The FDA Adverse Event Reporting System holds 6,817 reports that list ivabradine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 523 are coded as a death and 2,464 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as ivabradine?
16 other medicines are given the same way (oral) and in the same FDA class as ivabradine or labeled mainly for the same use (heart failure), the same class first. Heart failure lists all 37 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Carvedilol | Heart failure | 41 labelers | $0.0179 per tablet 6.25 mg tablet | No current entry |
| Spironolactone | Heart failure | 38 labelers | $0.0426 per tablet 25 mg tablet | A presentation being discontinued |
| Hydrochlorothiazide | Heart failure | 44 labelers | $0.0115 per tablet 25 mg tablet | A presentation being discontinued |
| Furosemide | Heart failure | 33 labelers | $0.026 per tablet 20 mg tablet | In shortage |
| Sacubitril and valsartan | Heart failure | 27 labelers | $0.533 per unit 49-51 mg | No current entry |
| Bumetanide | Heart failure | 24 labelers | $0.108 per tablet 1 mg tablet | Resolved |
| Digoxin | Heart failure | 21 labelers | $0.133 per tablet 125 mcg tablet | No current entry |
| Eplerenone | Heart failure | 9 labelers | $0.308 per tablet 25 mg tablet | No current entry |
Every medicine labeled for the same conditions as ivabradine
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does ivabradine compare with medicines for the same use?
3 side-by-side pages set ivabradine beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to ivabradine
- 16 medicines for the same use
- Ivabradine side effects
- the label's list beside FAERS reports
- Ivabradine shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other